Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

252 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Efficacy and safety of single-agent pertuzumab, a human epidermal receptor dimerization inhibitor, in patients with non small cell lung cancer.
Herbst RS, Davies AM, Natale RB, Dang TP, Schiller JH, Garland LL, Miller VA, Mendelson D, Van den Abbeele AD, Melenevsky Y, de Vries DJ, Eberhard DA, Lyons B, Lutzker SG, Johnson BE. Herbst RS, et al. Among authors: garland ll. Clin Cancer Res. 2007 Oct 15;13(20):6175-81. doi: 10.1158/1078-0432.CCR-07-0460. Clin Cancer Res. 2007. PMID: 17947484 Clinical Trial.
Phase II trial of erlotinib plus concurrent whole-brain radiation therapy for patients with brain metastases from non-small-cell lung cancer.
Welsh JW, Komaki R, Amini A, Munsell MF, Unger W, Allen PK, Chang JY, Wefel JS, McGovern SL, Garland LL, Chen SS, Holt J, Liao Z, Brown P, Sulman E, Heymach JV, Kim ES, Stea B. Welsh JW, et al. Among authors: garland ll. J Clin Oncol. 2013 Mar 1;31(7):895-902. doi: 10.1200/JCO.2011.40.1174. Epub 2013 Jan 22. J Clin Oncol. 2013. PMID: 23341526 Free PMC article. Clinical Trial.
Effect of Intermittent Versus Continuous Low-Dose Aspirin on Nasal Epithelium Gene Expression in Current Smokers: A Randomized, Double-Blinded Trial.
Garland LL, Guillen-Rodriguez J, Hsu CH, Yozwiak M, Zhang HH, Alberts DS, Davis LE, Szabo E, Merenstein C, Lel J, Zhang X, Liu H, Liu G, Spira AE, Beane JE, Wojtowicz M, Chow HS. Garland LL, et al. Cancer Prev Res (Phila). 2019 Nov;12(11):809-820. doi: 10.1158/1940-6207.CAPR-19-0036. Epub 2019 Aug 26. Cancer Prev Res (Phila). 2019. PMID: 31451521 Free PMC article. Clinical Trial.
Phase II study of the anti-insulin-like growth factor type 1 receptor antibody CP-751,871 in combination with paclitaxel and carboplatin in previously untreated, locally advanced, or metastatic non-small-cell lung cancer.
Karp DD, Paz-Ares LG, Novello S, Haluska P, Garland L, Cardenal F, Blakely LJ, Eisenberg PD, Langer CJ, Blumenschein G Jr, Johnson FM, Green S, Gualberto A. Karp DD, et al. Among authors: garland l. J Clin Oncol. 2009 May 20;27(15):2516-22. doi: 10.1200/JCO.2008.19.9331. Epub 2009 Apr 20. J Clin Oncol. 2009. PMID: 19380445 Retracted. Clinical Trial.
Safety, pharmacokinetics, and pharmacodynamics of the insulin-like growth factor type 1 receptor inhibitor figitumumab (CP-751,871) in combination with paclitaxel and carboplatin.
Karp DD, Pollak MN, Cohen RB, Eisenberg PD, Haluska P, Yin D, Lipton A, Demers L, Leitzel K, Hixon ML, Terstappen LW, Garland L, Paz-Ares LG, Cardenal F, Langer CJ, Gualberto A. Karp DD, et al. Among authors: garland l. J Thorac Oncol. 2009 Nov;4(11):1397-403. doi: 10.1097/JTO.0b013e3181ba2f1d. J Thorac Oncol. 2009. PMID: 19745765 Free PMC article. Clinical Trial.
252 results